1. Academic Validation
  2. Retinol Binding Protein 4 reactivates latent HIV-1 by triggering canonical NF-κB, JAK/STAT5 and JNK signalling

Retinol Binding Protein 4 reactivates latent HIV-1 by triggering canonical NF-κB, JAK/STAT5 and JNK signalling

  • Signal Transduct Target Ther. 2025 Oct 3;10(1):326. doi: 10.1038/s41392-025-02424-3.
Chiara Pastorio # 1 Khumoekae Richard # 2 Shariq Usmani # 1 Ann-Kathrin Kissmann # 3 Grigory Bolotnikov 3 Guillermo Gosálbez 1 Manuel Hayn 1 Lennart Koepke 1 Alina Sauertnik 1 Andrea Preising 1 Nico Preising 4 Ludger Ständker 4 Matthew Fair 2 Jessicamarie Morris 2 Emmanouil Papasavvas 2 Qin Liu 2 Honghong Sun 5 Armando Rodríguez 4 6 Karam Mounzer 2 Sebastian Wiese 6 Pablo Tebas 5 Yangzhu Du 5 Gregory M Laird 7 Markus Jaritz 8 Frank Rosenau 3 Moritz M Gaidt 8 Konstantin M J Sparrer 1 9 Luis J Montaner 2 Frank Kirchhoff 10
Affiliations

Affiliations

  • 1 Institute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
  • 2 HIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.
  • 3 Institute of Pharmaceutical Biotechnology, Ulm University, Ulm, Germany.
  • 4 Core Facility Functional Peptidomics (CFP), Ulm University Medical Center, Ulm, Germany.
  • 5 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA.
  • 6 Core Unit Mass Spectrometry and Proteomics (CUMP), Ulm University Medical Center, Ulm, Germany.
  • 7 AccelevirDx, Baltimore, MD, USA.
  • 8 Research Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria.
  • 9 German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.
  • 10 Institute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany. frank.kirchhoff@uni-ulm.de.
  • # Contributed equally.
Abstract

Reactivation of the latent viral reservoirs is crucial for a cure of HIV/AIDS. However, current latency reversing agents are inefficient, and the endogenous factors that have the potential to reactivate HIV in vivo remain poorly understood. To identify natural activators of latent HIV-1, we screened a comprehensive peptide/protein library derived from human hemofiltrate, representing the entire blood peptidome, using J-Lat cell lines harboring transcriptionally silent HIV-1 GFP reporter viruses. Fractions potently reactivating HIV-1 from latency contained human Retinol Binding Protein 4 (RBP4), the carrier of retinol (Vitamin A). We found that retinol-bound holo-RBP4 but not retinol-free apo-RBP4 strongly reactivates HIV-1 in a variety of latently infected T cell lines. Functional analyses indicate that this reactivation involves activation of the canonical NF-κB pathway and is strengthened by JAK/STAT5 and JNK signalling but does not require retinoic acid production. High levels of RBP4 were detected in plasma from both healthy individuals and people living with HIV-1. Physiological concentrations of RBP4 induced significant viral reactivation in latently infected cells from individuals on long-term antiretroviral therapy with undetectable viral loads. As a potent natural HIV-1 latency-reversing agent, RBP4 offers a novel approach to activating the latent reservoirs and bringing us closer to a cure.

Figures
Products